Explore

Trendline Trendline
Supermac's Wins UK Trademark Battle Against McDonald's

Supermac's Wins UK Trademark Battle Against McDonald's

Supermac's Wins UK Trademark Battle Against McDonald's
USA Today USA Today
Bank of America spends $250M yearly on GLP-1s for workers, CEO says

Bank of America spends $250M yearly on GLP-1s for workers, CEO says

Bank of America's CEO said the company spends more than $250 million a year on GLP-1 drugs for employees, calling the growing cost a worthwhile investment.
Trendline Trendline
Eli Lilly and Novo Nordisk Show Diverging Paths in Obesity Drug Market

Eli Lilly and Novo Nordisk Show Diverging Paths in Obesity Drug Market

Eli Lilly and Novo Nordisk Show Diverging Paths in Obesity Drug Market
Trendline Trendline
Verstappen Urges Dutch Government to Support Motorsport Post-Zandvoort

Verstappen Urges Dutch Government to Support Motorsport Post-Zandvoort

Verstappen Urges Dutch Government to Support Motorsport Post-Zandvoort
Trendline Trendline
Eli Lilly Outpaces Novo Nordisk in Obesity Drug Market Amid Earnings Reports

Eli Lilly Outpaces Novo Nordisk in Obesity Drug Market Amid Earnings Reports

Eli Lilly Outpaces Novo Nordisk in Obesity Drug Market Amid Earnings Reports
Trendline Trendline
Max Verstappen Urges Dutch Government Support Amid Motorsport Uncertainty

Max Verstappen Urges Dutch Government Support Amid Motorsport Uncertainty

Max Verstappen Urges Dutch Government Support Amid Motorsport Uncertainty
Trendline Trendline
Conan O'Brien's Travel Series Returns with New Destinations

Conan O'Brien's Travel Series Returns with New Destinations

Conan O'Brien's Travel Series Returns with New Destinations
Trendline Trendline
Femke Broeders-Bol Faces Realistic Expectations in European Athletics Championships

Femke Broeders-Bol Faces Realistic Expectations in European Athletics Championships

Femke Broeders-Bol Faces Realistic Expectations in European Athletics Championships
Reuters Reuters
Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo

Lilly beats estimates on resilient demand for injectable GLP-1 drugs, widens gap with Novo

By Mrinalika Roy and Mariam Sunny Aug 5 (Reuters) - Sales of Eli Lilly's Zepbound and Mounjaro injectable weight-loss and diabetes drugs soared during the second quarter, easily beating Wall Street estimates and widening the gap with Danish rival Novo Nordisk.
TheStreet TheStreet
Novo Nordisk CEO resets expectations for Wegovy's explosive growth

Novo Nordisk CEO resets expectations for Wegovy's explosive growth

I believe that when a stock is down nearly 10% year to date and down 38% over three years, the CEO's job on a quarterly earnings call is not just to report results. It is to rebuild a narrative that investors have lost confidence in. And Novo Nordisk CEO Mike Doustdar is honestly trying that with ...
Trendline Trendline
Conan O'Brien's Travel Series 'Conan O'Brien Must Go' Returns with New Season

Conan O'Brien's Travel Series 'Conan O'Brien Must Go' Returns with New Season

Conan O'Brien's Travel Series 'Conan O'Brien Must Go' Returns with New Season
Trendline Trendline
Freya von Noorden Pierce Reflects on Supermarket Experiences in Amsterdam

Freya von Noorden Pierce Reflects on Supermarket Experiences in Amsterdam

Freya von Noorden Pierce Reflects on Supermarket Experiences in Amsterdam